

Supplementary Table 1:
Distribution of Dosage Schedules Across Sites

<u>Site</u>	<u>SID</u>	<u>EED</u>	<u>LED</u>	<u>VED</u>	<u>Total</u>
A	111	33	29	178	351
B	24	44	6	32	106
C	51	12	7	58	128
D	254	1	82	8	345
E	124	105	0	0	229
F	2	12	0	0	14
G	305	0	0	86	391
H	111	0	112	0	223
I	98	39	1	16	154
V	0	0	32	1	33

Supplementary Table 2:
Number of full cases for each analysis.

<u>Measure</u>	<u>SID</u>	<u>EID</u>	<u>EED</u>	<u>LED</u>	<u>VED</u>
Full Data	1080	894	246	269	379
Gender	1080	894	246	269	379
Age	1080	894	246	269	379
BMI	596	609	187	243	179
JC Virus Status	900	824	232	260	332
JC Index	481	385	142	32	211
Prior use of Immunosuppressives	1052	887	245	266	376
Total NTZ Doses	1080	894	246	269	379
MRIs Reviewed	1011	893	246	268	379
T2 Lesions	946	849	234	255	360
Percentage of MRIs with T2 Gad Lesions	881	780	195	254	331
Percentage MRIs with Gad Lesions	1019	683	195	142	346
Total Relapses/ Relapse Rate/Patients with relapses	863	680	193	141	346
Total	1068	883	241	266	376
Steroids/Percentage of Participants on Steroids	960	622	203	148	271
All Radiological Activity	928	604	195	142	267
All Disease Activity	957	620	203	146	190
All Clinical Activity	819	580	192	134	254